Key Takeaways
- Revenue up, profit down on resets: FY25 revenue grew 13.1% and net profit 20.9%, but Q4 PAT fell 14.4% on a one-time prior-period cost adjustment; excluding it, profit was steady.
- UK roars, US stumbles: UK & Europe surged 17.2% YoY and 9.4% QoQ, while North America dropped 8% QoQ as government-funded clients cut discretionary spend and two clients began in-sourcing.
- Margins sacrificed for capability build: EBITDA de-grew 1.4% as growth came in newer, lower-margin Data & AI skills requiring on-site delivery, plus a one-time cost from organizational restructuring.
- Order backlog flat, but a $15 mn ACV deal signed just after quarter-end would lift it to 7–8% growth.
- What to watch next quarter: Whether the US reset and operational efficiency program start converting the 17–19% EBITDA margin ambition into visible progress, and if the UK margin dip from lower-margin government renewals begins to reverse.
UK & Europe: The Growth Engine
- Broad-based surge: Core UK & Europe delivered 17.2% YoY and 9.4% QoQ growth, with all cylinders firing across Digital, Data & AI, and Oracle services.
- Healthcare more than doubled: UK Healthcare grew over 100% YoY, driven by flagship policy programs in NHS prevention and collections, both Data & AI-led. Management expects significantly high growth to continue in FY26.
- Secured government renewals locked in: Almost all large backlog in secured government services has been renewed, providing a strong runway for the next 2 years. Two large single-sourced deals with the Home Office were won last quarter.
- Private sector turned a corner: UK private sector business is seeing good deals and healthy momentum, expanding beyond Digital and Oracle into Data & AI-led work.
- NHS merger is a non-event for now: The NHS England merger into the Department of Health is a 2-year process; cost savings target operations, not technology investment. No current deals have seen timeline changes or demand impact.
Umang Nahata: "there's nothing that we have heard so far, which would made us think in any view that we derail from where our current path was as far as NHS is concerned. So we are optimistic for a significant growth even in the next year."
North America: Reset Underway
- QoQ decline from uncertainty: North America grew 16% YoY but fell 8% QoQ. Two types of clients were affected: public sector and government-funded clients facing budget cuts and in-sourcing, and two private clients that began in-sourcing core areas. Some customers are right-shifting orders or asking to slow execution.
- Oracle business a bright spot: Oracle business in the US grew more than 50% YoY, led by healthcare providers. Manufacturing and utilities are seeing good uptake, with customers expanding from Oracle or Salesforce into data, IoT, and digital solutions.
- BCBS relationship narrowing: Blue Cross Blue Shield remains a strong customer with decent momentum, but expected business has reduced as they in-source more. No significant new Blue plan was added last year; management is negotiating MSAs with a few Blues and hopes to add more in the next 1–2 quarters.
- Structural reorganisation in progress: The US business is being reorganised from four individual businesses into an integrated structure, aligning more closely with Data & AI and an integrated Mastek view. This reset will take its course of time.
Margins: The Price of Capability Build
- EBITDA de-grew despite revenue growth: EBITDA fell 1.4% because growth in the UK came in newer skills (Data & AI, front-ending) with lower margins as capabilities are still being built, plus a one-time cost from organisational restructuring and lower US revenue flowing to the bottom line.
- UK margins dipped on government work: New NHS business and renewed secured government contracts were won at lower gross margins. NHS data solutions require on-site delivery in a secure government framework, causing an immediate margin dip. Large government renewals were direct-sourced to avoid competition but at lower rates. Management expects to restore margins over the midterm as the on-site/offshore mix improves.
- Subcontractor costs spiked: 70–80 new subcontractors were added this quarter, pushing up other expenses. Management expects this to balance over the coming 2–3 quarters.
- Headcount fell but on-site mix rose: Overall headcount reduced, but on-site resources increased, which are higher-cost.
- Operational efficiency program launched: A 4–5 step program covers internal overhead cost management, organisational simplification, AI adoption in delivery (targeting 15–20% efficiency), and reorganising the UK business for better resourcing pyramids and on-site/offshore mix.
Umang Nahata: "No, that doesn't change at all. Our ambition and drive is to drive to 17% to 19%. Like I said, there are some fundamental correction that we have made now. A lot of it is a cost of reset also. Some of it is also driving business in the right capability areas in U.K. as well as in U.S. So these will need some fundamental time to correct. But I'm sure before we end the next year, we will be in that range of 17% to 19%."
Data & AI: The Bet Being Built
- Team scaling fast: The Data & AI team is around 200–250 people, growing quarter-on-quarter, with plans to add another 50–100 through reskilling and new hires. This is expected to be the fastest-growing business area in the coming year.
- ADOPT.AI platform expanded: Launched in Q3 for Oracle services, the platform has now been extended to all service lines including Salesforce and Digital, offering 30–50% efficiency on fixed-bid projects.
- 100+ AI-led use cases developed: Many are in close conjunction with clients and going through initial POCs. Management is optimistic these will drive significant uptake.
- Efficiency gains shared with clients: On fixed-bid projects using AI-enabled technologies, customers are seeing more than 30% efficiency benefits. Mastek passes roughly 30% efficiency back to clients while remaining profitable.
- Asset accelerators and start-up investments: Investment in working with start-ups and acquiring platforms they have developed is a key part of executing the Data & AI business.
Umang Nahata: "We've already seen customers where we are seeing more than 30% efficiency benefits as we are executing, especially the fixed bid projects that we execute across Oracle, Digital and Salesforce using AI and AI-enabled technologies."
Order Book & Deal Dynamics
- Backlog flat, but post-quarter deal shifts the picture: The 12-month order backlog was flattish YoY on constant currency. A $15 million ACV contract closed in the first week of April; if included, backlog growth moves to 7–8%.
- Top 5 clients drove the quarter: Revenue addition came largely from the top 5 clients. March is when many customers go live with projects; management is now discussing next-phase work and expanded managed services.
- New customer additions continue: 11 new customers were added this quarter, maintaining a pace of 40–50 additions per year while reducing tail customers. Net new business potential also exists in existing customers around Data & AI.
- Working capital improved: DSOs improved to 83 days, which was the target. Cash generation grew more than 30% year-on-year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | Reach 17% to 19% range | Before end of FY26 |
| UK Healthcare growth | Significantly high growth to continue | FY26 |
| UK margins recovery | Return to healthy margin rates as on-site/offshore mix improves | Midterm, over next year |
| Subcontractor balance | 70–80 new subcontractors added this quarter to be balanced out | Coming 2–3 quarters |
| AI-driven internal efficiency | 15% to 20% efficiency drive from AI adoption in delivery | Ongoing |
| Blue Cross Blue Shield MSAs | Add a few more MSAs beyond BCBS | Next 1–2 quarters |
| Cerner investment | Invest when Oracle opens Cerner for partners | No date (conditional on Oracle) |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue from operations (FY25) | 13.1% growth, compared to FY24 |
| Net profit (FY25) | 20.9% growth, compared to FY24 |
| Cash and cash equivalents | ₹622 cr, up from ₹473 cr at end of FY24 |
| Final dividend | ₹16 per share, cumulative 460% for FY25 |
| EBITDA | de-grew 1.4% QoQ; impacted by lower-margin new business, one-time reset costs, and lower US revenue |
| Net profit | de-grew 14.4% QoQ; includes a one-time prior period cost adjustment |
| UK and Europe revenue | 17.2% growth YoY and 9.4% growth QoQ |
| North America revenue | ~16% growth YoY, 8% decline QoQ; macro uncertainty and in-sourcing by some clients |
| Oracle business (North America) | more than 50% growth in FY25 compared to FY24 |
| UK healthcare business | more than 100% growth YoY in FY25 |
| 12-month order backlog | 1.7% growth for FY25; would be closer to 7-8% including a $15M ACV contract closed in first week of April |
| Total active customers (North America) | 120-plus |
| New customers added | 11 in Q4; targeting 40-50 annually while reducing tail customers |
| Subcontractors added | 70-80 new subcontractors in Q4 |
| DSO | 83 days, improved from 81 days earlier in the fiscal; target for the fiscal achieved |
| Cash generation | more than 30% growth YoY |
| Data and AI team size | 200-250-plus people, adding another 50-100 |
| AI-led use cases developed | more than 100 |
| AI efficiency benefit on fixed-bid projects | more than 30% efficiency benefits observed |
| ADOPT.AI platform efficiency | 30% to 50% efficiency offered to customers |
| Internal AI adoption efficiency target | 15% to 20% efficiency drive targeted |
| NHS England merger timeline | at least 2 years for integration |